Long-term evaluation of the impact of the H1-receptor antagonist Cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis
Long-term evaluation of the impact of the H1-receptor antagonist Cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis
 
  The impact of the prolonged use of cetirizine at high dose (0.25 mg/kg twice a day over 18 mo) on behavior and cognitive ability was examined in a double-blind, randomized, placebo-controlled trial (ETAC—Early Treatment of the Atopic Child) designed to establish whether it was possible to prevent young children (1–2 y old at study entry) with atopic dermatitis from developing asthma. Well-validated and standardized measures of behavior (Behavior Screening Questionnaire) and cognition (McCarthy Scales of Children’s Abilities) were used. In addition, the ages of attainment of psychomotor milestones were established. These measures were taken between an average of 32 and 53 mo of age, both during the study treatment with cetirizine or placebo and after the study treatment had been discontinued. The Behavior Screening Questionnaire was completed at least once on approximately 300 children in each group and on approximately 200 children on five occasions. The McCarthy Scales of Children’s Abilities were administered to approximately 100 in each group at three different times. There were no significant differences between the cetirizine and placebo groups on either of the behavior and cognition measures or in psychomotor milestones during or after the study treatment. These findings suggest that there are no adverse effects on behavior or learning processes associated with the prolonged use of cetirizine in young children with atopic dermatitis.
Abbreviations:
ETAC, Early Treatment of the Atopic Child
BSQ, Behavior Screening Questionnaire
MSCA, McCarthy Scales of Children’s Abilities
GCI, General Cognitive Index
GMQ, Global Medical Questionnaire
  
  
  251-257
  
    
      Stevenson, Jim
      
        0c85d29b-d294-43cb-ab8d-75e4737478e1
      
     
  
    
      Cornah, Deborah
      
        de418379-0864-4cd5-826e-7a163f3d5090
      
     
  
    
      Evrard, Philippe
      
        d8ad55bb-e94e-42a1-b11a-89fc8be5a64c
      
     
  
    
      Vanderheyden, Valere
      
        d8c15048-2f2f-4e6d-aa5d-bb982c279862
      
     
  
    
      Billard, Catherine
      
        1596cf68-3922-4336-9617-fc3baa4a56c5
      
     
  
    
      Bax, Martin
      
        cc5e9f6b-3f57-4759-a2e1-b9a441920d88
      
     
  
    
      van Hout, Anne
      
        1603f6b0-a5e9-4e68-a79c-e1d039fcdd83
      
     
  
  
   
  
  
    
      1 January 2002
    
    
  
  
    
      Stevenson, Jim
      
        0c85d29b-d294-43cb-ab8d-75e4737478e1
      
     
  
    
      Cornah, Deborah
      
        de418379-0864-4cd5-826e-7a163f3d5090
      
     
  
    
      Evrard, Philippe
      
        d8ad55bb-e94e-42a1-b11a-89fc8be5a64c
      
     
  
    
      Vanderheyden, Valere
      
        d8c15048-2f2f-4e6d-aa5d-bb982c279862
      
     
  
    
      Billard, Catherine
      
        1596cf68-3922-4336-9617-fc3baa4a56c5
      
     
  
    
      Bax, Martin
      
        cc5e9f6b-3f57-4759-a2e1-b9a441920d88
      
     
  
    
      van Hout, Anne
      
        1603f6b0-a5e9-4e68-a79c-e1d039fcdd83
      
     
  
       
    
 
  
    
      
  
  
  
  
  
  
    Stevenson, Jim, Cornah, Deborah, Evrard, Philippe, Vanderheyden, Valere, Billard, Catherine, Bax, Martin and van Hout, Anne
  
  
  
  
   
    (2002)
  
  
    
    Long-term evaluation of the impact of the H1-receptor antagonist Cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis.
  
  
  
  
    Pediatric Research, 52 (2), .
  
   (doi:10.1203/01.PDR.0000024060.49308.89). 
  
  
   
  
  
  
  
  
   
  
    
      
        
          Abstract
          The impact of the prolonged use of cetirizine at high dose (0.25 mg/kg twice a day over 18 mo) on behavior and cognitive ability was examined in a double-blind, randomized, placebo-controlled trial (ETAC—Early Treatment of the Atopic Child) designed to establish whether it was possible to prevent young children (1–2 y old at study entry) with atopic dermatitis from developing asthma. Well-validated and standardized measures of behavior (Behavior Screening Questionnaire) and cognition (McCarthy Scales of Children’s Abilities) were used. In addition, the ages of attainment of psychomotor milestones were established. These measures were taken between an average of 32 and 53 mo of age, both during the study treatment with cetirizine or placebo and after the study treatment had been discontinued. The Behavior Screening Questionnaire was completed at least once on approximately 300 children in each group and on approximately 200 children on five occasions. The McCarthy Scales of Children’s Abilities were administered to approximately 100 in each group at three different times. There were no significant differences between the cetirizine and placebo groups on either of the behavior and cognition measures or in psychomotor milestones during or after the study treatment. These findings suggest that there are no adverse effects on behavior or learning processes associated with the prolonged use of cetirizine in young children with atopic dermatitis.
Abbreviations:
ETAC, Early Treatment of the Atopic Child
BSQ, Behavior Screening Questionnaire
MSCA, McCarthy Scales of Children’s Abilities
GCI, General Cognitive Index
GMQ, Global Medical Questionnaire
        
        This record has no associated files available for download.
       
    
    
   
  
  
  More information
  
    
      Published date: 1 January 2002
 
    
  
  
    
  
    
  
    
  
    
  
    
     
    
  
    
  
    
  
    
  
  
  
    
  
  
        Identifiers
        Local EPrints ID: 18373
        URI: http://eprints.soton.ac.uk/id/eprint/18373
        
          
        
        
        
          ISSN: 0031-3998
        
        
          PURE UUID: 2721eff7-cea0-43c4-abf5-844abbe28abd
        
  
    
        
          
            
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
  
  Catalogue record
  Date deposited: 06 Jan 2006
  Last modified: 15 Mar 2024 06:04
  Export record
  
  
   Altmetrics
   
   
  
 
 
  
    
    
      Contributors
      
        
      
          
          Author:
          
            
            
              Deborah Cornah
            
          
        
      
          
          Author:
          
            
            
              Philippe Evrard
            
          
        
      
          
          Author:
          
            
            
              Valere Vanderheyden
            
          
        
      
          
          Author:
          
            
            
              Catherine Billard
            
          
        
      
          
          Author:
          
            
            
              Martin Bax
            
          
        
      
          
          Author:
          
            
            
              Anne van Hout
            
          
        
      
      
      
    
  
   
  
    Download statistics
    
      Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
      
      View more statistics